According to a recent report [1] from the Cancer Research Agency of the World Health Organization, cancer is a dominant cause of mortality worldwide, leading to 10 million deaths in 2020 alone. Diagnosing a patient from the early stages tremendously raises the chance of survival. Current clinical cancer detection approaches including X-ray, magnetic resonance imaging (MRI), and biomarker analysis not only fail to provide a precise border of the malignant tissue, especially in the early stages of cancer, but also can be invasive and lead to tissue damage. Recent progress in EM biosensor technologies has the potential to deliver a point-of-care diagnosis and surpass conventional methods regarding accuracy, time, and cost.